ORYZON receives approval from AEMPS to start SATEEN: a Phase IIA clinical trial in Multiple Sclerosis with ORY-2001

MADRID, SPAIN and CAMBRIDGE MA.

• The company expects to start enrollment before year’s end

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced that it has received approval of a Clinical Trial Application (CTA), the European IND equivalent, from the Spanish Drug Agency (AEMPS) to conduct a PhaseIIA clinical study with ORY-2001 in patients of Multiple Sclerosis (MS).

Click here to see the full Press Release